Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Given every human being is totally unique, it’s no surprise our bodies often behave in different ways. So, while you should ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

The results were further supported by data from continuous glucose monitoring (CGM; Freestyle Libre Pro iQ), which was used by approximately 80% of patients in the study and reported in a separate ...

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...

Ltd. Boston Scientific (Bard® Stent System, Antibacterial Coating Technologies) Abbott Laboratories (Xience® Drug-Eluting ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...